News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
818,007 Results
Type
Article (74457)
Company Profile (644)
Press Release (742906)
Multimedia
Podcasts (126)
Webinars (14)
Section
Business (227519)
Career Advice (3721)
Deals (39312)
Drug Delivery (129)
Drug Development (89369)
Employer Resources (198)
FDA (17867)
Job Trends (17142)
News (387844)
Policy (38781)
Tag
Academia (2999)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (96)
Alliances (55992)
ALS (104)
Alzheimer's disease (1505)
Antibody-drug conjugate (ADC) (164)
Approvals (17822)
Artificial intelligence (309)
Autoimmune disease (29)
Automation (16)
Bankruptcy (403)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (440)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (313)
Cancer (2482)
Cardiovascular disease (210)
Career advice (3170)
Career pathing (34)
CAR-T (176)
Cell therapy (491)
Cervical cancer (22)
Clinical research (72284)
Collaboration (935)
Company closure (2)
Compensation (578)
Complete response letters (30)
COVID-19 (2868)
CRISPR (50)
C-suite (275)
Cystic fibrosis (109)
Data (2361)
Decentralized trials (2)
Denatured (43)
Depression (56)
Diabetes (302)
Diagnostics (6924)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (132)
Drug pricing (130)
Drug shortages (33)
Duchenne muscular dystrophy (104)
Earnings (94265)
Editorial (47)
Employer branding (25)
Employer resources (167)
Events (129103)
Executive appointments (788)
FDA (19296)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (826)
Gene editing (125)
Generative AI (28)
Gene therapy (363)
GLP-1 (860)
Government (5121)
Grass and pollen (6)
Guidances (150)
Healthcare (20874)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (152)
Indications (30)
Infectious disease (3031)
Inflammatory bowel disease (159)
Inflation Reduction Act (11)
Influenza (58)
Intellectual property (102)
Interviews (727)
IPO (17760)
IRA (51)
Job creations (4992)
Job search strategy (2593)
Kidney cancer (11)
Labor market (47)
Layoffs (564)
Leadership (24)
Legal (9915)
Liver cancer (82)
Lung cancer (349)
Lymphoma (161)
Machine learning (9)
Management (65)
Manufacturing (364)
MASH (81)
Medical device (14624)
Medtech (14629)
Mergers & acquisitions (22119)
Metabolic disorders (806)
Multiple sclerosis (89)
NASH (23)
Neurodegenerative disease (116)
Neuropsychiatric disorders (34)
Neuroscience (2120)
NextGen: Class of 2025 (7636)
Non-profit (5080)
Now hiring (41)
Obesity (433)
Opinion (275)
Ovarian cancer (83)
Pain (105)
Pancreatic cancer (91)
Parkinson's disease (162)
Partnered (22)
Patents (258)
Patient recruitment (119)
Peanut (51)
People (64125)
Pharmaceutical (133)
Pharmacy benefit managers (22)
Phase I (22340)
Phase II (31534)
Phase III (23768)
Pipeline (1397)
Policy (180)
Postmarket research (3256)
Preclinical (9865)
Press Release (72)
Prostate cancer (114)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (436)
Real estate (7146)
Recruiting (75)
Regulatory (26115)
Reports (58)
Research institute (2655)
Resumes & cover letters (579)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (82)
Series A (144)
Series B (94)
Service/supplier (26)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4201)
State (2)
Stomach cancer (16)
Supply chain (75)
Tariffs (54)
The Weekly (81)
Vaccines (822)
Venture capitalists (45)
Weight loss (306)
Women's health (39)
Worklife (20)
Date
Last 7 days (987)
Last 30 days (3166)
Last 365 days (34891)
2025 (12560)
2024 (37898)
2023 (42567)
2022 (53926)
2021 (58723)
2020 (57663)
2019 (51302)
2018 (39084)
2017 (36831)
2016 (37740)
2015 (43731)
2014 (38413)
2013 (34389)
2012 (36287)
2011 (36404)
2010 (35835)
Location
Africa (1192)
Alabama (61)
Alaska (7)
Arizona (249)
Arkansas (14)
Asia (48687)
Australia (8370)
California (6679)
Canada (2107)
China (574)
Colorado (289)
Connecticut (305)
Delaware (166)
Europe (110025)
Florida (977)
Georgia (226)
Hawaii (1)
Idaho (63)
Illinois (625)
India (30)
Indiana (342)
Iowa (12)
Japan (177)
Kansas (112)
Kentucky (28)
Louisiana (15)
Maine (70)
Maryland (992)
Massachusetts (5107)
Michigan (250)
Minnesota (430)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (69)
New Hampshire (69)
New Jersey (1878)
New Mexico (31)
New York (1876)
North Carolina (1142)
North Dakota (9)
Northern California (2877)
Ohio (224)
Oklahoma (15)
Oregon (46)
Pennsylvania (1463)
Puerto Rico (14)
Rhode Island (36)
South America (1566)
South Carolina (26)
South Dakota (1)
Southern California (2482)
Tennessee (108)
Texas (995)
United States (25445)
Utah (199)
Virginia (175)
Washington D.C. (72)
Washington State (611)
West Virginia (3)
Wisconsin (70)
818,007 Results for "takeda pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Takeda Pledges $30B in U.S., Argues Against Trump’s ‘Most Favored Nations’ Proposal
Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 trillion over the next 10 years.
May 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
May 5, 2025
·
3 min read
Collaboration
Takeda Pumps $770M Into Another BridGene Pact to Hit ‘Undruggable’ Targets
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket agreements with Keros Therapeutics, AC Immune and Degron Therapeutics in the past nine months.
February 25, 2025
·
2 min read
·
Tristan Manalac
Business
JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration
JCR Pharmaceuticals Co., Ltd. announced today that Takeda Pharmaceutical Co., Ltd. (“Takeda”) decided to discontinue their collaboration with JCR to develop gene therapies using adeno-associated viruses (AAV) combined with the JCR J-Brain Cargo ® Technology.
December 21, 2023
·
4 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Press Releases
AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Completion of Sample Set for the Strategic Partnership Implemented to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
May 9, 2025
·
3 min read
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.
March 3, 2025
·
2 min read
·
Annalee Armstrong
Business
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while responding positively to the announcement that Julie Kim will take the helm of the Japanese giant in 2026.
January 30, 2025
·
1 min read
·
Dan Samorodnitsky
Huntington’s disease
Takeda Walks Away From Wave Huntington’s Partnership After Sinking $260M in Collaboration
Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on Wave’s WVE-003 clinical-stage Huntington’s disease program—a potential $5 billion commercial opportunity, according to the biotech.
October 16, 2024
·
3 min read
·
Tristan Manalac
1 of 81,801
Next
